RA CAPITAL MANAGEMENT, L.P. - 09 Nov 2022 Form 3 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Role
Director, 10%+ Owner
Signature
/s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.
Issuer symbol
ACRV
Transactions as of
09 Nov 2022
Net transactions value
$0
Form type
3
Filing time
09 Nov 2022, 19:30:35 UTC
Previous filing
10 Nov 2022
Next filing
16 Nov 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ACRV Series B Preferred Stock 09 Nov 2022 Common Stock 994,706 See footnotes F1, F2, F4
holding ACRV Series B Preferred Stock 09 Nov 2022 Common Stock 426,302 See footnotes F1, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series B Preferred Stock is convertible into shares of Common Stock, on a 1-for-2.466 basis, into the number of shares of Common Stock without payment of further consideration at any time at the holder's election and will convert immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date.
F2 These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund").
F3 These securities are held directly by RA Capital Nexus Fund II, L.P. (the "Nexus Fund II").
F4 RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and the Nexus Fund II. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

Remarks:

Dr. Derek DiRocco, a Partner of the Adviser, serves on the board of directors for the Issuer.